Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology
How do you approach duration of immunotherapy in patients with metastatic NSCLC?
Does your approach depend on the patient’s response or PD-L1 level? Are there any studies supporting immunotherapy’s use beyond 2 years?